Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
Healthcare
$16.62 +0.58%
+$0.04 today
- Market cap
- $3.04B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
52W Low $4.40High $10.08
Volume 2.56M
Average 1.66M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$28.63M
FY 2025 · Annual
Investing Cash Flow
-$696,000.00
FY 2025 · Annual
Financing Cash Flow
$11.39M
FY 2025 · Annual
-68.5% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| Deferred Income Tax | (1.42M) | (1.42M) | (1.25M) | (2.27M) | 0 |
| Stock-Based Compensation | 11.38M | 12.16M | 10.72M | 18.36M | 22.37M |
| Change in Working Capital | 11.85M | (35.15M) | (6.29M) | (8.82M) | (10.36M) |
| Accounts Receivables | (13.37M) | (13.37M) | (8.37M) | (1.22M) | (10.64M) |
| Inventory | (7.47M) | (7.47M) | (14.8M) | (8.78M) | (19.29M) |
| Accounts Payables | (4.32M) | (4.32M) | 6.96M | (9.61M) | (69K) |
| Other Working Capital | 19.98M | (9.99M) | 9.92M | 10.79M | 19.63M |
| Other Non-Cash Items | 3.5M | 3.52M | (1.1M) | (2.05M) | 3.91M |
| Operating Cash Flow | (102.89M) | (102.89M) | (47.02M) | (36.98M) | 28.63M |
| Capital Expenditures | (524K) | (524K) | (2.26M) | (868K) | (696K) |
| Acquisitions (Net) | 38.47M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (43.02M) | 0 | (43.74M) | (34.49M) | 0 |
| Sales of Investments | 34.99M | 34.99M | 40M | 40.24M | 0 |
| Other Investing Activities | 4.55M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 34.46M | 34.46M | (6M) | 4.88M | (696K) |
| Debt Repayment | 0 | 102.72M | 0 | 38.17M | 9.17M |
| Common Stock Issued | 27M | 30M | 581K | 0 | 13.1M |
| Common Stock Repurchased | (534K) | (468K) | (1.01M) | (3.73M) | (10.88M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.78M) | (604K) | 1.73M | 0 |
| Financing Cash Flow | 27.25M | 127.47M | (1.61M) | 36.17M | 11.39M |
| Effect of Forex Changes | (3K) | (4.35M) | 0 | 0 | 0 |
| Net Change in Cash | 59.04M | 59.04M | (54.64M) | 4.07M | 39.32M |
| Free Cash Flow | (103.42M) | (103.42M) | (49.29M) | (37.85M) | 27.93M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$554.0K
+ D&A$12.2M
+ Stock-Based Comp$22.4M
+ Deferred Tax$0
- Working Capital-$10.4M
+ Other Non-Cash$3.9M
= Operating Cash Flow$28.6M
- Capex-$696.0K
= Free Cash Flow$27.9M
Analysis
FY2025 free cash flow is $27.9M. FCF conversion is 5041.5% of net income. Operating cash flow was $28.6M, with capex of -$696.0K. The largest bridge item is Stock-Based Comp at $22.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 |
Does XERS generate free cash flow?
Xeris Biopharma Holdings, Inc. (XERS) generated $27.93M of free cash flow in fiscal 2025.
How much operating cash flow does XERS produce?
Operating cash flow was $28.63M, before capital expenditures of $696,000.00.
Continue the stock analysis
Jump to another research area for this company.